



Table of Contents 
I. Abstract…………………………………….. p. 3 
II. Systematic background review……………..p. 5 
III. Original research section…………………… p. 15 
III. Tables and Figures…………………………. p. 28 
IV. Appendix…………………………………… p. 32 















(1) To describe parents’ report of special needs for children with Attention Deficit Hyperactivity 
Disorder (ADHD) on the Children with Special Health Care Needs (CSHCN) Screener; and (2) 
to assess the association between responses to CSHCN Screener items and annual mental health 
and total health expenditures per child. 
Methods 
In pooled 2002-11 Medical Expenditure Panel Survey (MEPS) data, we identify children ages 4-
17 years with ADHD. We used OLS regression to model the relationship between CSHCN 
Screener items and mental health and total health expenditures. Using regression coefficients, we 
estimated adjusted, average total health expenditures for children with ADHD – both with and 
without a co-morbid mental health condition – and different combinations of positive Screener 
items.  
Results 
There were 3,883 children with ADHD in the sample.  Without a co-morbid mental health 
condition, average total expenditures per year were $508 for those meeting no Screener items, 
$1,434 for those meeting only the medication use item, $1,979 for those meeting the medication 
use and counseling need items, and $2,371 for those meeting the medication use, counseling 
need, and use of more health services items.  Children with a co-morbid mental health condition 
had greater total health expenditures for each combination of Screener items.  The associations 
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between Screener items and mental health expenditures were similar, but with a slightly lower 
marginal effect of the medication use item (p<0.001 for all comparisons).   
Conclusions 
Parents’ responses on the CSHCN Screener are associated with meaningful variation in 
expenditures for children with ADHD.  Though cross-sectional, this study suggests that the 
CSHCN Screener can identify associations between the heterogeneity of needs for children with 
ADHD and differences in their use of and expenditures for health services.   
 
Key Words: Attention Deficit Hyperactivity Disorder (ADHD), Medical Expenditure Panel 
Survey (MEPS), Children with Special Health Care Needs (CSHCN), CSHCN Screener 
Significance: Compared to prevailing methods that use clinical or administrative data to estimate 
expenditure differences across clinical subgroups of children with ADHD, parents’ reports of 
special needs on the CSHCN Screener are associated with similar estimates of expenditure 
differences.  Use of the CSHCN Screener may be a more efficient, family-centered method of 








Research Question and Systematic Review 
  
Attention deficit hyperactivity disorder (ADHD) affects between 3% and 9% of school-
aged children in the United States (Brown et al., 2001; Wolraich et al., 2011) and often persists 
into adulthood (Biederman et al., 1996; Kessler et al., 2005).  Children with ADHD have higher 
rates of injury and chronic health conditions, particularly mental health problems such as conduct 
disorder and anxiety, than do children without ADHD (Guevara, Lozano, Wickizer, Mell, & 
Gephart, 2001; Leibson, Katusic, Barbaresi, Ransom, & O'Brien, 2001; Szatmari, Offord, & 
Boyle, 1989).  Treatment for ADHD and its comorbidities leads to increased use of medical care; 
affected children use more outpatient mental health visits, primary care, and medications (Chan, 
Zhan, & Homer, 2002; Guevara et al., 2001).   
In this paper we begin to work towards two goals for the population of children with 
ADHD in the United States.  Our objectives were as follows: (1) To identify subgroups of 
children with ADHD by parents’ responses on the Children with Special Health Care Needs 
Screener; and (2) To assess differences in mental health and total health expenditures across 
those subgroups of children with ADHD.  In this first section we describe our systematic 
literature search on the following question: How does clinical variation among children with 
ADHD relate to expenditures for their care?  We then describe the findings of that search by 








Systematic Literature Search 
 We used a systematic search strategy but did not limit results by specific interventions, 
comparison groups, or outcomes.  To understand better how clinical variation among children 
with ADHD relates to health expenditures, I searched PubMed/MEDLINE in February 2015 
using the following search strategy: 
("Costs and Cost Analysis"[MeSH] OR "Economics"[MeSH] OR "economics 
"[Subheading] OR "Cost-Benefit Analysis"[MeSH] OR "Cost Allocation"[MeSH] OR 
"Cost of Illness"[MeSH] OR "Health Care Costs"[MeSH] OR "Direct Service 
Costs"[MeSH]) AND ("Attention Deficit Disorder with Hyperactivity" OR "ADHD" OR 
"Attention Deficit") 
I limited the search with additional PubMed filters for English-language publications and those 
focused on children from birth to 18 years of age.  I considered for inclusion any articles that met 
all the following additional criteria: including children in the US between ages 4-18 years with 
ADHD, including some description or analysis of health costs or expenditures, published 




The initial search yielded 353 results, all relevant to humans.  After review of titles and 
abstracts, 59 articles were pulled for full-text review.  The disposition of these articles is outlined 
in Figure I.  After full-text review, 33 articles were excluded, leaving 26 articles included for 
background review for this study. 
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 Search findings are summarized in Table 1.  Studies broadly described that children with 
ADHD cost money to society in several ways: health care costs, education-related costs, and lost 
work productivity for caregivers.(Birnbaum et al., 2005; Doshi et al., 2012)  In particular, health 
care for children with ADHD has been repeatedly estimated to cost about twice that for healthy 
children.(Burd, Klug, Coumbe, & Kerbeshian, 2003; Chan, Zhan, & Homer, 2002; J. Guevara, 
Lozano, Wickizer, Mell, & Gephart, 2001; Jones & Foster, 2009; Leibson, Katusic, Barbaresi, 
Ransom, & O'Brien, 2001; Ray et al., 2006; Swensen et al., 2003).  These higher costs are 
largely attributable to use of prescription medication to treat ADHD and to more outpatient visits 
with physicians to manage ADHD medications.(Chan et al., 2002; J. Guevara et al., 2001; 
Records identified through  
database searching 
(n = 353) 
Records screened 
(n = 353) 
Records excluded 
(n = 294) 
Full-text articles 
assessed for eligibility 
(n = 59) 
Full-text articles excluded, with reasons: 
 
Not relevant to study question (n = 21) 
 
Study population not 4-17 years old (n = 2) 
 
Not original research (n = 3) 
 
Non-US study population (n = 5) 
 
Published before 2000 (n = 2) 
Studies included in 
qualitative synthesis 
(n = 26) 
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Leibson et al., 2001)  However, education-related costs are difficult to measure even though 
many suspect that they represent substantial, additional costs of caring for children with ADHD.( 
Doshi et al., 2012; Marks et al., 2009)  Inflation-adjusted costs of caring for children with ADHD 
have been increasing over time, a trend thought to reflect the growth in off-label use of anti-
psychotic medications to treat children with ADHD.(Fullerton et al., 2012; J. Guevara, Lozano, 
Wickizer, Mell, & Gephart, 2002; Matone et al., 2012; Sikirica et al., 2012) 
 The articles reviewed for this study did suggest several consistent variables that drive 
cost/expenditure differences within the population of children who have ADHD.  In addition to 
prescription medication, which was used in 60 – 90% of children with ADHD (Fullerton et al., 
2012; Zima et al., 2010), the presence of a co-morbid mental health condition such as depression 
or conduct disorder was associated with much higher health care expenditures, particularly for 
outpatient mental health specialty care, inpatient care, and medications.(Boles, Lynch, & DeBar, 
2001; DeBar, Lynch, & Boles, 2004; J. Guevara et al., 2001; J. P. Guevara, Mandell, Rostain, 
Zhao, & Hadley, 2003; Jones & Foster, 2009; Radigan, Lannon, Roohan, & Gesten, 2005)  
Distinguishing further, amongst the largest clinical group of children with ADHD – those 
without a co-morbid mental health condition and treated only with a single medication – the 
type/brand of medication has a meaningful effect on health expenditures over one to two 
years.(Barner, Khoza, & Oladapo, 2011; Marchetti et al., 2001)  But even though use of 
prescription medication accounts for the largest individual share of costs for ADHD care, 
individual children with ADHD who also receive counseling or psychotherapy have greater 
health expenditures than children treated with medication alone.(Jensen et al., 2005; Sikirica et 
al., 2012; Stein & Orlando, 2001)  Those who receive counseling tend to have private insurance 
and be more likely to have co-morbid mental health conditions.(Stevens, Harman, & Kelleher, 
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2005)  Finally, the make-up of health services that compose overall health expenditures for 
children with ADHD differs by demographic factors.  Non-minority children and those with 
private insurance are more likely to have higher expenditures for medications, whereas minority 
children and those with public insurance are more likely to have higher expenditures for ER 
visits.(Hudson, Miller, & Kirby, 2007; Stevens et al., 2005)  
 
Discussion (and gaps, strengths/limitations of review) 
This review was limited by the reliance on a single database, by the lack of an additional 
reviewer, and by the heterogeneity of outcomes used in the included studies.  All but two of the 
studies included in this systematic review were cross-sectional or observational studies.  The one 
randomized, controlled trial and one systematic review provide relatively higher quality 
evidence, but overall in this review the level of evidence was low for assessing the relationships 
between clinical variables that distinguish children with ADHD from one another and the 
expenditures for their care.  Those clinical features of ADHD that seem to be consistently 
associated with greater health expenditures are as follows: use of non-stimulant prescription 
medications such as anti-psychotics, particularly when multiple medications are used; presence 
of a comorbid psychiatric condition such as conduct disorder; and treatment approaches that use 
counseling with frequent outpatient visits.  There are likely additional differences in expenditures 
among children with ADHD that are related to their relative degree of impairment, but the 
clinical information associated with expenditure differences in this review may not capture these 
degrees of impairment.  Parents’ perceptions of their children’s needs may provide additional 
insight into their relative impairment and relate to meaningful differences in health expenditures. 
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Table 1. Characteristics of Included Studies 
First author, Year Study design Component(s) of 
Clinical Variation 
Related to Expenditures 
Outcome(s) Other Characteristics 
Barner JC, 2011 Cross-sectional  x Type of prescription 
medication 
x Treatment with non-stimulant 
medications more expensive 
than with stimulant 
medications 
Analysis of claims data for 62,789 Texas 
children with ADHD insured by Medicaid 
Birnbaum H, 2005 Case-control x Treatment vs. non-
treatment of ADHD 
with prescription 
medication or therapy  
x Treatment leads to additional 
health expenditures > 
$500/year/child 
Analysis of claims data for children (n=1,048) 
and adults insured by a single private 
company; compared to healthy controls in the 
same plan 
Boles M, 2001 Cross-sectional  x Comorbid psychiatric 
condition 
x Children with ADHD and 
psychiatric comorbidity are 
more likely to use multiple 
medications, incur higher 
expenditures 
Analysis of medical record and claims data in 
a single, large HMO for 1,941 children aged 5 
to 12 years with ADHD 
Burd L, 2003 Case-control x Cost of ADHD vs. 
healthy controls 
x Children with ADHD 
incurred 11% higher health 
expenditures compared to 
healthy controls 
Analysis of claims data for North Dakota state 
health plan; 7,745 children with ADHD 
Chan E, 2002 Case-control x Cost of ADHD vs. 
healthy controls 
x Comorbid psychiatric 
condition 
x Children with ADHD had 
almost two times higher 
health expenditures than did 
healthy controls 
x Children with ADHD and 
comorbid psychiatric 
condition had higher 
expenditures than did 
children with ADHD alone 
Comparison of 165 children with ADHD in 
the 1996 Medical Expenditure Panel Survey to 
healthy, matched controls 
DeBar LL, 2004 Cross-sectional  x Comorbid psychiatric 
condition 
x Children with comorbid 
psychiatric condition used 
more specialty mental health 
care and prescription 
medications than did children 
with ADHD alone; their care 
was also more expensive 
overall 
Analysis of medical record and claims data in 
a single, large HMO for 1,617 children aged 5 
to 12 years with ADHD 
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Doshi JA, 2012 Systematic review x Categories of 
additional 
expenditures for 
children with ADHD  
x Compared to healthy 
children, children with 
ADHD had higher costs for 
health care and education 
Systematic review of costs for children with 
ADHD and for their families across multiple 
systems including health and education 
Fullerton CA, 2012 Cross-sectional  x Growth in ADHD-
related expenditures 
over time 
x Spending on prescription 
medications for ADHD was 
the fastest-growing category 
of expenditures (200% 
increase over 10 years), 
driven largely by an almost 
600% increase in spending 
on antipsychotics 
Repeated cross-sectional analyses over 10 
years of children with ADHD enrolled in 
Medicaid in Florida 
Guevara J, 2001 Case-control x Cost of ADHD vs. 
healthy controls 
x Comorbid psychiatric 
condition 
x Children with ADHD had 
about two times greater 
health expenditures than did 
healthy controls 
x Children with ADHD and 
comorbid psychiatric 
condition had even greater 
expenditures 
Retrospective analysis of 2,992 children with 
ADHD, insured by one HMO in Washington; 
matched to healthy controls 1:4 
Guevara J, 2002 Case-control x Type of prescription 
medication 
x Children with ADHD had six 
times the odds as healthy 
controls of diagnosis with a 
non-ADHD behavioral 
disorder and had higher odds 
of being prescribed non-
stimulant psychotropic 
medications 
Retrospective analysis of 2,992 children with 
ADHD, insured by one HMO in Washington; 
matched to healthy controls 1:4 
Guevara J, 2003 Retrospective 
observational cohort 
x Cost of ADHD vs. 
healthy controls 
x Children with ADHD and 
other disruptive disorders had 
higher expenditures than 
healthy children and similar 
to children with physical 
conditions 
Retrospective analysis using the Medical 
Expenditure Panel Survey of health 
expenditures for children with behavioral 
disorders, emotional disorders, or physical 
disorders, compared to those of healthy 
children 
Hudson JL, 2007 Cross-sectional x Racial/ethnic 
differences in 
stimulant prescription 
x White children had twice the 
odds of being prescribed 
stimulants as did black and 
Hispanic children; they also 
had higher expenditures 
Analysis of reported stimulant prescriptions 
and health expenditures for children with 




Jensen PS, 2005 Randomized 
controlled trial 
x Cost of different 
treatment approaches 
in ADHD 
x Intensive counseling was six 
times more expensive than 
medical management alone, 
but had similar rates of 
successful treatment 
Six-site randomized trial including 579 
children with ADHD, randomized to medical 
management alone, counseling alone, both 
combined, or neither 
Jones DE, 2009 Prospective 
observational cohort 
x Cost of ADHD vs. 
healthy controls 
x Comorbid psychiatric 
condition 
x Children with ADHD alone 
had twice the health 
expenditures as did healthy 
children 
x Children with ADHD and 
conduct disorder had twice 
the health expenditures as did 
children with ADHD alone 
Analysis of service use and expenditures for 
children with and without ADHD in a multi-
site cohort 
Leibson CL, 2001 Retrospective 
observational cohort 
x Cost of ADHD vs. 
healthy controls 
x For children diagnosed with 
ADHD, 9-year median health 
expenditures were more than 
twice those for children not 
diagnosed with ADHD 
Analysis of medical records and billing claims 
for 4,880 children in a birth cohort in 
Rochester, MN 
Marchetti A, 2001 Cross-sectional, 
descriptive survey 
x Type of prescription 
medication 
x Treatment with 
methylphenidate 
formulations was less 
expensive than treatment 
with dextroamphetamine 
salts 
Comparison of expected costs to families of 
treatment with different stimulant preparations 
Marks DJ, 2009 Cross-sectional x School costs for 
children with ADHD 
x Children with ADHD used 
more occupational therapy, 
speech and language therapy, 
and other special education 
services; they also incurred 
higher educational costs 
related to those services 
Baseline analysis of 206 preschool children’s 
(109 with ADHD, 97 without) use of special 
education and related services, and related 
costs, at the beginning of a 5-year cohort study 
Matone M, 2012 Cross-sectional x Type of prescription 
medication 
x Although children with 
autism, schizophrenia, and 
bipolar disorder were more 
likely to be prescribed anti-
psychotic medication, 
children with ADHD were 
the largest consumers of 
these medicines 
Repeated cross-sectional analysis of the 
Medicaid Analytic Extract for all 50 states and 
the District of Columbia 
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Radigan M, 2005 Cross-sectional x Type of prescription 
medication 
x Comorbid psychiatric 
disorder 
x Children with ADHD and a 
comorbid psychiatric 




Analysis of prescription medications used in 
Medicaid-enrolled children with ADHD in 
New York state 
Ray GT, 2006 Case-control x Cost of ADHD vs. 
healthy controls 
x Racial/ethnic 
differences in ADHD 
costs 
x Compared to those of 
children without ADHD, 
health expenditures for 
children with ADHD were 
higher for two years before 
and two years after diagnosis 
x White children with ADHD 
had higher health 
expenditures than did Asian 
Americans, African 
Americans, and Hispanic 
Americans  
Analysis of medical record and claims data for 
3,122 children with ADHD and 15,899 
children without ADHD, enrolled in a health 
system in northern California 
Sikirica V, 2012 Case-control x Type of prescription 
medication 
x Children with ADHD and no 
comorbid psychiatric 
condition prescribed atypical 
anti-psychotic medications 
had almost two times higher 
health expenditures than did 
similar children prescribed 
only stimulant medications 
Retrospective analysis of claims data from a 
single commercial insurance plan for 22,622 
children aged 6-12 years and diagnosed with 
ADHD; children treated with atypical anti-
psychotic medications were matched 1:1 using 
propensity scores to children treated with 
stimulant medications 
Stein B, 2001 Cross-sectional x Medical vs. 
combined medical 
and psychological 
treatment of ADHD 
x Even after controlling for 
indicators of severity, 
expenditures for children 
with ADHD treated with 
medical and psychological 
therapy were significantly 
greater than those for 
children treated with medical 
therapy alone 
Cross-sectional analysis of claims from a 
behavioral health contractor; included 2,137 
children with ADHD 
Stevens J, 2005 (1) Cross-sectional x Type of prescription 
medication 
x Children treated with long-
acting stimulants had higher 
health expenditures than 
those treated with short-
acting stimulants 
Cross-sectional analysis of health expenditures 
for 221 children with ADHD in the 2000 and 
2001 Medical Expenditure Panel Survey 
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Stevens J, 2005 (2) Cross-sectional x Racial/ethnic 
differences in ADHD 
treatment and costs 
x Children in minority racial 
and ethnic groups had lower 
odds of diagnosis with 
ADHD and lower 
expenditures for ADHD 
treatment than did white 
children 
Cross-sectional analysis of ADHD diagnosis, 
related services, and related expenditures in 
the 1997-2000 Medical Expenditure Panel 
Survey; n = 1,061 
Swensen AR, 2003 Case-control x Costs of ADHD 
compared to healthy 
controls 
x Children with ADHD had 
almost three times higher 
health expenditures than did 
children without ADHD 
Analysis of claims data from a self-insured 
manufacturing corporation 
Zima BT, 2010 Prospective 
observational cohort 
x Medical vs. 
psychological 
treatment of ADHD 
x Children with ADHD who 
received psychological 
treatment (without 
medication) in specialty 
mental health clinics had 
more visits and higher related 
expenditures than did 
children who received 
medical treatment (without 
psychological treatment) in 
primary care 
Non-interventional study of 530 children with 
ADHD aged 5 to 11 years; all lived in the 
same county and were insured by Medicaid 
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Parent-Reported Health Consequences in Children with ADHD: Implications for Expenditures 
Introduction 
 Treatment for ADHD and its comorbidities leads to increased use of medical care; 
affected children use more outpatient mental health visits, primary care, and medications (Chan, 
Zhan, & Homer, 2002; Guevara et al., 2001).  In general, medical care for children with ADHD 
costs more than twice that for unaffected children and about the same as for children with asthma 
(Chan et al., 2002; Guevara et al., 2001; Leibson et al., 2001). 
Among children with ADHD, stimulant medication use, a co-morbid mental health 
condition, and white race are associated with higher costs (Chan et al., 2002; Guevara et al., 
2001; Ray et al., 2006).  However, reliance on information from administrative and demographic 
data may not adequately capture the spectrum of health consequences that children with ADHD 
experience.  They frequently have emotional, developmental, and behavioral impairments in 
addition to diagnosable, co-morbid disorders (Lollar, Hartzell, & Evans, 2012; Szatmari et al., 
1989; Zentall, 1993).  These impairments may not meet established criteria for diagnosis and so 
may be difficult to measure, but they may lead to differences in the costs of caring for a child 
with ADHD.  For example, a child with ADHD and communication impairment may require 
more intensive and costly behavioral therapy to achieve similar improvements to those of 
another not similarly impaired.  For children with ADHD, parent report can potentially capture 
costly health consequences that elude diagnosis and typical, clinical forms of measurement. 
Understanding the cost implications of heterogeneity within diagnostic groups is integral 
to evolving notions of quality that focus on value, or the relationship of the costs of care to 
outcomes important to individuals and families (Forrest & Silber, 2014; Zima et al., 2013).  
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Furthermore, better understanding of the spectrum of needs and costs in common diagnostic 
groups may improve effectiveness of health care payment models – such as accountable care 
organizations – that shift some responsibility for cost and quality to care providers.  Data 
gathered from parents provide family-centered perspectives for these developing models. 
 In this study, we first describe the spectrum of needs among children with ADHD using 
the Children with Special Health Care Needs (CSHCN) Screener, which uses parent report to 
identify “children…who have or are at increased risk for a chronic physical, developmental, 
behavioral, or emotional condition and who also require health and related services of a type or 
amount beyond that required by children generally” by the consequences of their health 
conditions (McPherson et al., 1998).  Child health policymakers, planners, and researchers have 
widely adopted this definition and the CSHCN Screener for identifying children in need of 
additional services and at risk for higher health-related costs.  Children with ADHD are likely to 
meet the CSHCN Screener items because they frequently use medication and counseling services 
and have behavior problems at school and home.   
 Next, we examine the association of CSHCN Screener items with mental health and total 
health expenditures for children with ADHD.  We explore how parent-reported health 
consequences in children with ADHD, captured by the items of the CSHCN screener, are 
associated with variation in health expenditures for children with ADHD – framed using the 








 The Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease 
Control and Prevention conduct the Medical Expenditure Panel Survey (MEPS) to provide 
nationally representative data on families’ and individuals’ care needs, use of health services, 
health expenditures, and household finances (Ezzati-Rice, Rohde, & Greenblatt, 2008).  Since 
2000, the MEPS has also incorporated the questions of the CSHCN Screener.  For this study we 
pooled annual, cross-sectional data on families raising a child with ADHD in 2002 through 2011.  
The Institutional Review Board of the University of North Carolina – Chapel Hill determined 
that this study was exempt from review because it used publicly available, de-identified data.  
The study was conducted in accordance with prevailing ethical principles. 
Study Population 
 The sample for this study consisted of all children in the MEPS database aged 4 to 17 
years with ADHD.  We excluded children up to age 4 years because guidelines discourage 
diagnosis until that time (Wolraich et al., 2011).  We identified children with ADHD using 
diagnosis code 314 of the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM).  MEPS coders assign ICD-9-CM codes to individual children based 
on professional review of parent-reported conditions, medical visits, and other services used 
(Cohen, 1997). 
 




 The outcome measures were individual, annual mental health care expenditures and total 
health care expenditures.  Expenditures in the MEPS are calculated using an algorithm that 
incorporates information on payments reported by families and by their medical providers and 
that imputes missing payment information based on estimated expenditures for services (Machlin 
& Dougherty, 2007).  We defined mental health expenditures as the sum of those for outpatient 
and inpatient visits with psychotherapy, a psychotherapeutic drug prescription, or a mental health 
diagnosis, and for psychotherapeutic drugs.  We identified psychotherapeutic drugs using class 
242 of the Multum classification system, which the MEPS uses to organize prescription drugs 
("MEPS HC144A Codebook: 2011 Prescribed Medicines").  Total health care expenditures were 
calculated as the sum of expenditures for all care, including mental health, and included the 
following categories: outpatient visits (including speech therapy), inpatient stays, prescription 
medicines, home health care, dental visits, emergency room visits, durable medical and vision 
equipment, physical and occupational therapy, chiropractor visits, vision care, and a category for 
other.  We adjusted expenditures for inflation to 2011 dollars using the Consumer Price Index.  
The independent variables of interest were the five items of the CSHCN Screener 
(Appendix).  Screener items assess the presence for at least 12 months of the following 
consequences of chronic illness: (1) prescription medication use; (2) use of more medical, mental 
health, or educational services compared to other children; (3) limitation of functional abilities 
compared to other children; (4) use of physical, occupational, or speech therapy; and (5) 
treatment or counseling for an emotional, developmental, or behavioral problem (McPherson et 
al., 1998).  The five items relate to three definitional domains of CSHCN: dependency (item 1), 
service use (items 2, 4, and 5), and functional limitations (item 3)(CAHMI, 2014). 
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 Control variables included predisposing variables (age, sex, minority race or ethnicity, 
living in a single-adult household, residence in a rural area, and family income as a percentage of 
the federal poverty level), enabling variables (having a parent with a college degree and ever 
being uninsured during the year), and one need variable (presence of a co-morbid psychiatric 
condition) (Gelberg et al., 2000).  We identified co-morbid psychiatric conditions in children 
with ADHD using the ICD-9-CM codes 294-298 (bipolar disorder, schizophrenia, and 
psychoses), 299 (pervasive developmental disorders), 300 (anxiety), 301 (personality disorders), 
311 (depression), and 312-313 (conduct and emotional disorders).  Based on prior work we 
expected that older children, those from families with higher incomes, those with a parent having 
a college degree, those continuously insured, and those with a co-morbid mental health condition 
would have greater expenditures, and that children of minority races or ethnicities, those living in 
a single-adult household, and those living in a rural area would have lower expenditures (Chan et 
al., 2002). 
Statistical Analysis 
 We used descriptive statistics to characterize the sample of children with ADHD by study 
variables.  We used t-tests to assess unadjusted differences in mental health and total health 
expenditures by Screener item.  To model the relationship between Screener items and total 
health expenditures, we used ordinary least squares (OLS) regression.  Because some children 
had no mental health expenditures, we used logistic regression to estimate the odds of any mental 
health expenditure by Screener items, then OLS regression for those with mental health 
expenditures.  In both models we included Screener items as separate dichotomous variables to 
obtain estimates for each item’s association with expenditures, adjusted for covariates.  We log-
transformed expenditures because they were not normally distributed. 
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 We estimated total health expenditures for clinical subgroups (by CSHCN Screener 
items) of children with ADHD using regression coefficients from the OLS regression models.  
We calculated adjusted, average total health expenditures for children with ADHD – both with 
and without a co-morbid mental health condition – and different combinations of positive 
Screener items.  For those calculations we used the sample average for all other covariates.  We 
also ran regressions using the number of Screener items met in place of the set of dichotomous 
Screener items.  A two-sided alpha of 0.05 was used as the threshold for statistical significance.  
All statistical analyses were performed using the SURVEY procedures in SAS version 9.2 to 
weight the data and account for the complex sample design.  The DOMAIN statement was used 
to provide accurate estimates for the population subgroup of interest (children with ADHD), 




 We identified 3,883 children with ADHD, a weighted prevalence of 4.5% (Table 1).  
These children tended to be male (73.4%) and non-Hispanic white (72.9%).  About 27% of the 
children lived in single-adult households, with about 33% having a college-educated parent.  
About 20% of the households in our sample reported family income less than 100% of the 
Federal Poverty Level.  Just over 11% of children in the sample were uninsured at some point 
during the year, and just over 20% had a comorbid mental health condition.   
Nearly two-thirds (63%) met at least two CSHCN Screener items (Table 1), but range of 
impairment by number of Screener items met was wide, with 15% of the sample meeting no 
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Screener items and 19%  meeting four or five.  Children with ADHD most commonly met the 
prescription medication item (75%), followed by the need for counseling (53%), use of more 
health services (48%), functional limitations (20%) and need for special therapies (18%) items. 
CSHCN Screener and Health Expenditures 
 In unadjusted analyses, a positive response for each individual CSHCN Screener item 
was associated with greater mental health and total expenditures (Table 2).  For mental health 
expenditures, positive responses to the prescription medication and need for counseling items 
were associated with the largest relative increases ($1,189 and $1,168 per year, respectively), but 
the remaining three items were also associated with higher mental health expenditures (all 
p<0.001).  For total health expenditures, positive responses were associated with increases from 
a low of $1,685 for the need for special therapies item to a high of $2,297 for the functional 
limitations item (all p<0.001). In separate analyses we also found that a positive response to each 
Screener item was associated with greater expenditures for non-mental health care and that 
increasing number of positive Screener items was associated with greater mental health and total 
health expenditures (not shown). 
 In adjusted analyses, three Screener items – use of prescription medication, use of more 
health services, and need for counseling – were associated with greater total health and mental 
health expenditures (Table 3).  Compared to children with ADHD who did not meet each 
respective Screener item, those who met the prescription medication use item had 2.8 times 
greater total expenditures, those who met the use of more health services item 1.2 times greater 
total expenditures, and those who met the counseling need item 1.4 times greater total 
expenditures (exponentiated OLS regression coefficients, all p<0.001; Table 3).  For mental 
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health expenditures, the prescription medication use, use of more health services, functional 
limitations and counseling need Screener items were all associated with odds of any expenditure 
(p<0.03 for each; results not shown).  Among children who had any mental health expenditures, 
those who met the prescription medication use, use of more health services, or counseling need 
Screener items had 2.3 times, 1.2 times, and 1.4 times greater mental health expenditures, 
respectively (exponentiated OLS regression coefficients, all p<0.001; Table 3).  The functional 
limitations screener was not associated with greater mental health expenditures in OLS 
regression.  Total health costs were higher for those with a co-morbid mental health condition or 
a parent with a college degree; mental health costs were higher for those with a co-morbid 
mental health condition.  Total health and mental health costs were lower for children uninsured 
at any point in the year; total health costs were also lower for those of a minority race or 
ethnicity and for poorer families (Table 3). 
 Figure 1 presents estimates of total health expenditures for children with ADHD to 
highlight their variation across combinations of Screener items and presence of a co-morbid 
mental health condition.  For children with ADHD but without a co-morbid mental health 
condition, average total expenditures per year were $508 for those meeting no Screener items, 
$1,434 for those meeting only the medication use Screener item, $1,979 for those meeting the 
medication use and counseling need Screener items, and $2,371 for those meeting the medication 
use, counseling need, and use of more health services Screener items (Figure 1).  Children with 
a co-morbid mental health condition had greater total health expenditures: $864 for those 
meeting no Screener items, $2,441 for those meeting the medication use Screener item, $3,369 
for those meeting the medication use and counseling need Screener items, and $4,036 for those 




 For children with ADHD, parents’ responses on the CSHCN Screener were associated 
with incremental differences in mental health and total health expenditures.  In particular, 
positive response to the medication use Screener item was associated with 2.8 times greater total, 
annual health expenditures for children with ADHD, while the counseling need and use of more 
health services Screener items were associated with  1.4 and 1.2 times greater expenditures, 
respectively (estimates obtained by exponentiation of regression coefficients for each Screener 
item; Table 3).  Having a co-morbid mental health condition was associated with 1.7 times 
greater total, annual expenditures.  The associations with mental health expenditures were 
similar, but with a slightly lower marginal effect of the medication use item.  The functional 
limitations and use of special therapies Screener items were not associated with marginal 
differences in either mental health or total health expenditures for children with ADHD. 
 These findings demonstrate that the CSHCN Screener is strongly associated with 
expenditures for children with ADHD.  While it is not surprising that the care of children who 
need medicine or counseling or who use more health care services would be more expensive, the 
contribution of this study is the understanding that parents’ report of those health consequences 
is associated with meaningful differences in the costs of caring for subgroups of children with 
ADHD.  Estimates in this paper do not reflect expected ADHD-specific costs of care for an 
individual child, because other chronic conditions, regional differences in care, and family and 
physician preferences all affect costs on an individual level.  However, population management-
focused approaches like ACOs will need simple, efficient ways of gathering information from 
patients and families, and ways of using that information to understand and anticipate the costs 
of providing care to children with the same diagnosis but also significant variability.  
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Approaches such as this one will be useful for calculating estimates more nuanced than those 
that use administrative data alone and potentially more feasible and patient-centered than 
gathering sufficient administrative data for individual risk-adjustment.  Additional research 
should also explore whether the items of the CSCHN Screener can reliably predict health 
expenditures for groups of children with ADHD and other chronic conditions.   
 Previous research studies provide reference points for understanding our findings on 
variation among children who have ADHD.  Using the 1996 MEPS, Chan et al. found that 
children with ADHD treated with stimulant medications incurred $1,447 in average yearly health 
care costs, compared to $535 for children with ADHD not treated with stimulants (Chan et al., 
2002).  Although that study measured stimulant use by counting prescriptions while ours used 
parents’ response to the medication use CSHCN Screener item, the marginal effect of medication 
use was similar in both studies (2.7 times average expenditures for ADHD without medication 
use in Chan et al., 2.8 times expenditures in our study).  That study was limited by its sample 
size (165 children with ADHD) in assessing additional variation among children with ADHD.   
Guevara et al. found that mental health care comprised $222 of the $1,465 per year in 
average health care costs for children with ADHD covered by a large health maintenance 
organization in Washington State, or 1.2 times average costs for those not using mental health 
services ($1,465/[$1,465-$222]) (Guevara et al., 2001).  In our study, parents’ responding 
positively to the need for counseling Screener item was associated with 1.4 times greater 
expenditures than for children whose parents responded negatively.  Additionally, Guevara and 
colleagues found that having ADHD and another mental health condition added $812 per year to 
health care costs, while having ADHD alone added $375 (Guevara et al., 2001).  Adding those 
incremental costs to the median yearly cost of care for children without ADHD in that study 
25 
 
($282) yields estimates for total yearly costs of $657 for children with ADHD alone and $1,094 
for children with ADHD and a co-morbid mental health condition, or 1.7 times greater costs for 
those having another mental health condition.  The marginal effect of having a co-morbid mental 
health condition in our study was similar (exponentiated regression coefficient 1.7) across 
combinations of screener items.  Taken together, these comparisons suggest that using CSHCN 
Screener items to characterize expenditure differences across subgroups of children with ADHD 
did not distort the previously described relationships between categories of health service use 
and expenditures.  
Our use of nationally representative data pooled across multiple years strengthens the 
generalizability of these findings.   Moreover, this study builds on previous research in this area 
by integrating parents’ report of children’s special needs on the CSHCN Screener with 
traditional use of diagnostic and health service codes.  The designers of the CSHCN Screener 
recently highlighted this approach as a way to use patient-centered data to inform the 
administrative data that health systems routinely collect (Bethell et al., 2014).  Understanding 
how families view the health needs of their children with ADHD, and how those views are 
associated with meaningful differences in health expenditures, is important to ongoing efforts to 
measure quality and to improve systems of care in ways that are important to families. 
Unlike previous studies (Chan et al., 2002; Guevara et al., 2001; Leibson et al., 2001) 
ours did not adjust for the marginal effects of other chronic conditions on health expenditures.  
Our rationale was to characterize expenditure differences associated with subgroups of children 
with ADHD, rather than to estimate expenditures attributable to ADHD.  The CSHCN Screener 
items, the presence of a co-morbid mental health condition, and the other covariates we chose 
reflect the spectrum of ADHD in ways that we felt having diabetes or cancer would not.  The 
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result of not adjusting for other chronic conditions is that the relationships described here 
between CSHCN Screener items and expenditures partially reflect care for other medical 
problems.  This approach adheres to the intended use of the Screener, which differentiates 
children by the consequences of their conditions, rather than by the conditions themselves 
(Bramlett, Read, Bethell, & Blumberg, 2009).  It also reflects recent work that used the CSHCN 
Screener items in the MEPS to profile the health services use and costs of children with medical 
complexity (Kuo et al., 2014). 
Limitations 
 Our study has several limitations that should be considered when reviewing its findings. 
Using the MEPS likely underestimates the true costs of caring for children with ADHD, since 
school systems frequently provide counseling, educational services, and even physical and 
occupational therapy that the MEPS does not capture.  The inability to include expenditures for 
these services in our analysis may be a reason why the functional limitations and use of special 
therapies Screener items were not associated with higher mental health or total expenditures in 
this study.  Also, with cross-sectional data we cannot determine whether children who meet more 
Screener items go on to incur greater expenditures, or whether parents of children who have 
incurred more expenditures are more likely to respond positively to the CSHCN Screener.  
Though both explanations likely underlie the relationship between Screener items and 
expenditures, this limitation does not diminish the CSHCN Screener’s utility in identifying 
subgroups children with ADHD who have meaningfully different expenditures.  Pooling data 
across a decade may obscure changes in the diagnosis and treatment of ADHD over time such 
that relationships between Screener items and expenditures might differ earlier vs. later in the 
time window.  However, the number of positive Screener items in children with ADHD was 
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similar across years, suggesting that parents’ perceptions of children’s needs were similar over 
time.   
Conclusions 
For children with ADHD, the CSHCN Screener items about the need for medication, 
need for counseling, and use of more health services are associated with higher mental health and 
total health expenditures.  The CSHCN Screener may be a simple tool to anticipate variation in 
expenditures for children with ADHD by using parent report.  These findings are an incremental 
step toward using parent or patient report to identify efficiently how the different needs and 
impairments of individuals within diagnostic groups affect use and cost of health services.  
Future research should assess the predictive validity of CSHCN Screener items for identifying 















Table 1. Description of Sample – Children with ADHD (n=3,883) 
Characteristic              n* Weighted %† 
Female 1038 26.6 
Age 
     4-7 
     8-12 










     White, non-Hispanic 
     Black, non-Hispanic 
     Other, non-Hispanic 











Rural residence 764 19.4 
Parent with college degree 878 32.8 
Single-adult household 1337 26.9 
Family income as % of poverty 
     <100% 
     100% - <125% 
     125% - <200% 
     200% - <400% 













Ever uninsured during year 459 11.3 
CSHCN Screener items 
     1. Prescription medications 
     2. Elevated service use 
     3. Functional limitations 
     4. Special therapies 













Number of CSHCN Screener items met 
     0 
     1 
     2 
     3 
     4 















Co-morbid mental health condition 801 21.7 
*Unweighted, sample n 











Table 2. Description of Expenditures According to Screener Items for Children with ADHD 
            Total Health Expenditures        Mental Health Expenditures 
Screener Item and Response 
 
Mean $/year p value* Mean $/year p value* 
Prescription medications 
     No 








Use of more health services 
     No 









     No 









     No 









     No 


























Table 3. OLS Regression Models for the Association of Positive Responses to CSHCN Screener 
Items (1-5) with Health Expenditures among Children with ADHD* 





(95% CI) p value Regression 
coefficient 
(95% CI) p value 
Intercept 
 
6.49 (6.18, 6.79) <0.001 5.72 (5.45, 5.99) <0.001 
1.  Prescription   
     medications 
1.04 (0.88, 1.20) <0.001 0.85 (0.70, 0.99) <0.001 
2.  Use of more health 
     services 
0.18 (0.08, 0.28) <0.001 0.22 (0.10, 0.32) <0.001 
3.  Functional 
     limitations 
0.05 (-0.08, 0.18) 0.47 -0.02 (-0.15, 0.11) 0.76 
4.  Special therapies 
      
0.10 (-0.04, 0.23) 0.18 0.08 (-0.05, 0.22) 0.23 
5.  Counseling needs 
      
0.32 (0.21, 0.44) <0.001 0.34 (0.23, 0.44) <0.001 
Co-morbid mental 
health condition 
0.53 (0.40, 0.66) <0.001 0.54 (0.40, 0.67) <0.001 
Age 
 
-0.01 (-0.02, 0.01) 0.58 0.00 (-0.02, 0.01) 0.90 
Female 
  
0.03 (-0.07, 0.13) 0.58 -0.09 (-0.20, 0.02) 0.12 
Minority race/ethnicity -0.22 (-0.35, -0.09) <0.001 -0.07 (-0.17, 0.03) 0.19 
Rural residence 
 
0.04 (-0.10, 0.17) 0.57 0.02 (-0.10, 0.15) 0.72 
Parent with college 
degree 
0.20 (0.07, 0.34) 0.003 0.03 (-0.11, 0.16) 0.70 
Ever uninsured during 
year 
-0.46 (-0.66, -0.26) <0.001 -0.25 (-0.44, -0.07) 0.009 
Family income as % of 
poverty 
     <100% 
     100% - <125% 
     125% - <200% 
     200% - <400% 











































*OLS for log amount of expenditures 









Figure 1. Model-Based Estimates of Total Yearly Expenditures for Specified Combinations of 


























No Screener Items Medication Use Medication Use and
Counseling
Medication Use,
Counseling, and Use of
More Health Services
ADHD ADHD + Co-morbid mental health condition





*From the Child and Adolescent Health Measurement Initiative (CAHMI); accessed on 12/15/2015 at 
http://www.cahmi.org/projects/children-with-special-health-care-needs-screener/ and reproduced with 
permission (personal email from Caitlin Murphy, 2/3/15). 
Figure Captions 
Figure 1: The Children with Special Health Care Needs Screener (reproduced with permission from the 
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